LEXICON PHARMACEUTICALS, INC.

LXRX

LEXICON PHARMACEUTICALS, INC.

LXRX

Insider Sentiment (TTM):

Last Purchase:2026-02-25Last Sale:-Shares Purchased (TTM):1,874,150Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:321,819,830Shares Outstanding:400,240,000Institutional Ownership Pct.:80.41%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	41	38	34	50	21	63	67	35	36	96	22	21
Short Term Investments	150	133	62	66	118	132	171	224	274	259	148	197
Accounts Receivable Net Current	2	12	2	2	2	47	3	3	3	2	1	0
Inventory Net	1	0	0	0	0	0	0	1	1	1	0	0
Other Assets Current	3	3	3	4	4	3	5	7	8	7	5	4
Assets Current	197	186	102	123	145	246	246	269	321	365	177	223
Property Plant And Equipment Net	2	2	2	2	2	2	2	2	2	2	2	2
Goodwill	45	45	45	45	45	45	45	45	45	45	45	45
Operating Lease Right Of Use Asset	7	7	7	8	4	5	5	5	5	5	6	6
Restricted Cash	0	29	29	29	29	-	0	-	-	-	-	-
Other Assets Noncurrent	0	0	0	0	0	0	0	1	1	1	1	1
Assets	250	269	185	206	226	298	298	321	373	417	229	276
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	2	3	3	4	6	11	15	14	12	8	14	12
Accrued Liabilities Current	12	7	13	14	11	13	30	22	16	15	17	20
Contract With Customer Liability	-	-	-	-	-	45	-	-	-	-	-	-
Contract With Customer Liability Current	-	-	-	4	17	-	-	-	-	-	-	-
Long Term Debt Current	0	0	5	-	-	42	0	-	-	-	-	-
Liabilities Current	15	10	21	22	35	111	45	36	28	23	32	32
Long Term Debt Noncurrent	51	50	49	57	56	59	100	100	99	100	100	99
Operating Lease Liability Noncurrent	-	-	-	-	-	-	-	-	-	5	5	5
Other Liabilities Noncurrent	9	6	7	8	5	5	7	7	6	-	5	-
Liabilities	76	66	77	86	96	175	152	143	133	128	136	137
Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	2,228	2,224	2,130	2,127	2,124	2,120	2,117	2,116	2,113	2,108	1,863	1,859
Retained Earnings Accumulated Deficit	-2,050	-2,019	-2,018	-2,002	-1,989	-1,993	-1,967	-1,933	-1,869	-1,815	-1,767	-1,717
Accumulated Other Comprehensive Income Loss Net Of…	-0	-0	0	0	-0	0	0	0	-0	-0	0	-0
Treasury Stock Value	-3	-3	-5	-5	-5	-5	-5	-5	-5	-5	-3	-3
Stockholders Equity	175	203	108	120	129	123	146	179	240	289	93	140
Accumulated Depreciation Depletion And Amortizatio…	-	-	3	-	-	-	2	2	2	5	5	4
Liabilities And Stockholders Equity	250	269	185	206	226	298	298	321	373	417	229	276
Preferred Stock Par Or Stated Value Per Share	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Preferred Stock Shares Authorized	5	5	5	5	5	5	5	5	5	5	5	5
Preferred Stock Shares Issued	3	3	2	2	2	2	2	2	2	2	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	-	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	900	450	450	450	450	450	450	450	450	450	450	300
Common Stock Shares Issued	447	426	366	366	366	366	363	363	363	248	246	246
Shares Outstanding	447	426	366	366	-	-	363	-	-	-	-	-
Treasury Stock Common Shares	2	2	2	2	2	2	2	2	2	2	1	1

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	29.76%	51.79%	36.31%	-	-	-	-	-	-	-	-	-
2025	45.28%	69.81%	101.89%	-4.35%	21.74%	23.48%	0.00%	-13.99%	18.88%	0.61%	2.44%	31.71%
2024	-4.71%	8.82%	17.06%	7.65%	-2.35%	22.35%	-34.86%	-27.52%	-30.28%	46.15%	82.05%	69.23%
2023	-	-	-	-	-	-	0.88%	34.21%	59.65%	-22.17%	-16.51%	-14.15%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	13.37	18.79	4.88	5.64	4.16	2.22	5.44	7.45	11.51	15.58	5.60	6.92
Quick Ratio	13.29	18.77	4.87	5.63	4.16	2.22	5.44	7.43	11.49	15.56	5.58	6.91
Working Capital	181.87M	176.13M	81.03M	100.81M	110.25M	135.11M	200.95M	232.56M	292.97M	341.25M	145.00M	191.11M
Leverage & Debt
Debt to Equity	0.43	0.33	0.72	0.71	0.74	1.42	1.04	0.80	0.56	0.44	1.46	0.98
Interest Coverage TTM	-	-	-	-	-	-	-	-	-50.54	-31.74	-22.36	-17.68
Debt Ratio	0.30	0.25	0.42	0.42	0.43	0.59	0.51	0.44	0.36	0.31	0.59	0.50
Efficiency & Turnover
Asset Turnover TTM	0.17	0.25	0.21	0.27	0.20	0.09	0.12	0.02	0.01	0.01	0.01	0.00
Days Sales Outstanding TTM	16.84	155.20	21.46	13.46	14.99	286.00	26.32	113.93	169.48	148.04	170.66	110.05
Receivables Turnover TTM	21.68	2.35	17.01	27.12	24.35	1.28	13.87	3.20	2.15	2.47	2.14	3.32
Per Share Metrics
Diluted EPS TTM	-0.14	-0.07	-0.14	-0.19	-0.33	-0.49	-0.63	-0.60	-0.65	-0.79	-0.80	-0.64
Free Cash Flow Per Share TTM	-0.15	-0.10	-0.19	-0.20	-0.29	-0.47	-0.57	-0.58	-0.63	-0.76	-0.73	-0.55
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	99.14%	99.49%	99.45%	99.41%	99.18%	98.03%	98.02%	93.43%	92.30%	94.73%	-	-
Operating Profit Margin TTM	-131.43%	-34.79%	-98.21%	-94.31%	-202.45%	-567.88%	-634.20%	-4,101.75%	-5,536.81%	-8,440.35%	-15,472.97%	-26,231.59%
Net Profit Margin TTM	-147.38%	-37.46%	-101.08%	-96.72%	-206.30%	-567.36%	-644.78%	-4,204.25%	-5,678.76%	-8,787.20%	-15,956.67%	-26,665.03%
Growth Metrics
Net Revenue Growth (1Y)	-29.08%	122.86%	60.24%	1,277.52%	1,542.85%	1,318.52%	2,700.09%	769.43%	727.67%	1,484.89%	698.56%	1,500.00%
Net Income Growth (1Y)	-49.33%	-85.29%	-74.88%	-68.31%	-40.32%	-8.41%	13.15%	37.08%	54.61%	75.34%	73.74%	62.64%
EPS Growth (1Y)	-57.94%	-86.69%	-77.86%	-68.47%	-48.94%	-37.93%	-21.82%	-7.12%	1.86%	35.06%	30.22%	16.14%
Valuation Metrics
P/E TTM	-17.19	-23.93	-8.29	-7.15	-2.86	-0.94	-1.18	-2.62	-2.58	-3.04	-1.91	-1.69
P/B TTM	6.02	3.08	3.88	4.08	2.67	1.35	1.62	3.18	2.18	2.04	3.63	1.91
P/S TTM	25.33	8.97	8.38	6.92	5.90	5.33	7.62	110.27	146.73	267.33	304.80	450.96
Market Cap	1.05B	624.37M	417.51M	490.59M	345.13M	166.55M	236.82M	567.54M	522.20M	588.94M	338.33M	266.97M
Enterprise Value	1.06B	606.97M	408.19M	468.44M	350.87M	204.36M	270.46M	632.89M	586.09M	592.32M	415.37M	345.12M
Calculated Values
Free Cash Flow TTM	-64.99M	-38.80M	-67.85M	-73.70M	-103.79M	-169.57M	-180.93M	-208.39M	-196.17M	-185.64M	-162.37M	-134.63M
Net Debt	10.51M	-17.41M	-9.32M	-22.15M	5.74M	37.81M	33.64M	65.34M	63.88M	3.38M	77.04M	78.15M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-02-25Purchase

Owner: Debbane, Raymond

Title: -

Shares: 2,000

Price/Share: $1.49

Value: $2,980.00

Shares Owned: 1,906,186

Relationship: Director

Ownership: Direct

2026-02-23Purchase

Owner: Debbane, Raymond

Title: -

Shares: 100,000

Price/Share: $1.47

Value: $147,000.00

Shares Owned: 1,904,186

Relationship: Director

Ownership: Direct

2026-02-20Purchase

Owner: Debbane, Raymond

Title: -

Shares: 100,000

Price/Share: $1.48

Value: $148,000.00

Shares Owned: 1,804,186

Relationship: Director

Ownership: Direct

2026-02-18Purchase

Owner: Debbane, Raymond

Title: -

Shares: 133,688

Price/Share: $1.32

Value: $176,468.16

Shares Owned: 1,654,186

Relationship: Director

Ownership: Direct

2026-02-02Purchase

Owner: Artal, Group S.A., Artal …

Title: -

Shares: 1,538,462

Price/Share: $1.30

Value: $2,000,000.60

Shares Owned: 1,538,462

Relationship: Director,TenPercentOwner

Ownership: Indirect

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-02-25	Debbane, Raymond	Director	-	Direct	Purchase	2,000	1.49	$2,980.00	1,906,186	4
2026-02-23	Debbane, Raymond	Director	-	Direct	Purchase	100,000	1.47	$147,000.00	1,904,186	4
2026-02-20	Debbane, Raymond	Director	-	Direct	Purchase	100,000	1.48	$148,000.00	1,804,186	4
2026-02-18	Debbane, Raymond	Director	-	Direct	Purchase	133,688	1.32	$176,468.16	1,654,186	4
2026-02-02	Artal, Group S.A., Artal …	Director,TenPercentOwner	-	Indirect	Purchase	1,538,462	1.30	$2,000,000.60	1,538,462	4
2023-11-16	Coats, Lonnel	Director,Officer	Chief Executive Officer	Direct	Purchase	90,000	1.05	$94,500.00	914,359	4
2023-11-13	Amouyal, Philippe	Director	-	Direct	Purchase	200,000	1.01	$202,000.00	240,332	4
2023-11-10	Coats, Lonnel	Director,Officer	Chief Executive Officer	Direct	Purchase	10,000	1.01	$10,100.00	824,359	4
2023-10-12	Debbane, Raymond	Director	-	Direct	Purchase	148,820	1.03	$153,284.60	1,340,847	4
2023-09-14	Wade, Jeffrey L	Officer	President and CFO	Direct	Purchase	10,000	1.38	$13,800.00	264,341	4
2023-08-04	Mcdermott, Wendy	Officer	VP, Human Resources	Direct	Purchase	6,000	1.84	$11,040.00	28,478	4
2023-06-29	Coats, Lonnel	Director,Officer	Chief Executive Officer	Direct	Purchase	10,000	2.16	$21,600.00	814,359	4
2023-06-26	Coats, Lonnel	Director,Officer	Chief Executive Officer	Direct	Purchase	10,000	2.18	$21,800.00	804,359	4
2023-06-23	Mcdermott, Wendy	Officer	VP, Human Resources	Direct	Purchase	10,000	2.43	$24,300.00	22,478	4
2023-06-22	Coats, Lonnel	Director,Officer	Chief Executive Officer	Direct	Purchase	40,000	2.31	$92,400.00	784,359	4
2023-06-20	Wade, Jeffrey L	Officer	President and CFO	Direct	Purchase	12,000	2.34	$28,080.00	254,341	4
2023-06-05	Artal, Group S.A., Artal …	Director,TenPercentOwner	-	Indirect	Purchase	27,775,050	2.60	$72,215,130.00	78,634,381	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

80.41%

Inst. Shares: 321,819,830

Shares Outstanding: 400,240,000

2025-12-31

71.22%

Inst. Shares: 258,555,591

Shares Outstanding: 363,053,000

2025-09-30

70.46%

Inst. Shares: 256,041,897

Shares Outstanding: 363,399,000

2025-06-30

69.50%

Inst. Shares: 252,480,075

Shares Outstanding: 363,294,000

2025-03-31

63.04%

Inst. Shares: 228,237,908

Shares Outstanding: 362,073,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	321,819,830	400,240,000	80.41%
2025-12-31	258,555,591	363,053,000	71.22%
2025-09-30	256,041,897	363,399,000	70.46%
2025-06-30	252,480,075	363,294,000	69.50%
2025-03-31	228,237,908	362,073,000	63.04%
2024-12-31	296,786,430	320,031,000	92.74%
2024-09-30	287,428,955	361,492,000	79.51%
2024-06-30	278,455,133	310,836,000	89.58%
2024-03-31	171,524,665	245,390,000	69.90%
2023-12-31	63,717,115	221,130,000	28.81%
2023-09-30	70,464,294	244,925,000	28.77%
2023-06-30	72,207,995	204,783,000	35.26%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

LEXICON PHARMACEUTICALS, INC. (LXRX) — SEC Financial Statements & Analysis

LEXICON PHARMACEUTICALS, INC. (LXRX) is a pharmaceutical preparations company, incorporated in DE. LEXICON PHARMACEUTICALS, INC. trades on Nasdaq as: LXRX. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), LEXICON PHARMACEUTICALS, INC. reported a -29.08% year-over-year revenue growth, a Gross Profit Margin of 99.14% (TTM), a Debt-to-Equity ratio of 0.43x, a Price-to-Sales (P/S) ratio of 25.33x (TTM), a Price-to-Book (P/B) ratio of 6.02x (TTM), at a market cap of $1.05B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -29.08%
Gross Profit Margin TTM: 99.14%
Debt To Equity: 0.43x
P/S TTM: 25.33x
P/B TTM: 6.02x
Market Cap: $1.05B

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is LEXICON PHARMACEUTICALS, INC. in?

LEXICON PHARMACEUTICALS, INC. (LXRX) operates in the Pharmaceutical Preparations industry.

What is LXRX's market cap?

LEXICON PHARMACEUTICALS, INC. (LXRX) has a market capitalization of $1.05B as of 2026-06-30.

What exchange does LXRX trade on?

LEXICON PHARMACEUTICALS, INC. (LXRX) trades on the Nasdaq.

Where is LEXICON PHARMACEUTICALS, INC. incorporated?

LEXICON PHARMACEUTICALS, INC. is incorporated in DE.